Publications
Detailed Information
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Robson, Mark | - |
dc.contributor.author | Ruddy, Kathryn J. | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Senkus, Elzbieta | - |
dc.contributor.author | Xu, Binghe | - |
dc.contributor.author | Domchek, Susan M. | - |
dc.contributor.author | Masuda, Norikazu | - |
dc.contributor.author | Li, Wei | - |
dc.contributor.author | Tung, Nadine | - |
dc.contributor.author | Armstrong, Anne | - |
dc.contributor.author | Delaloge, Suzette | - |
dc.contributor.author | Bannister, Wendy | - |
dc.contributor.author | Goessl, Carsten | - |
dc.contributor.author | Degboe, Arnold | - |
dc.contributor.author | Hettle, Robert | - |
dc.contributor.author | Conte, Pierfranco | - |
dc.date.accessioned | 2022-03-22T09:10:30Z | - |
dc.date.available | 2022-03-22T09:10:30Z | - |
dc.date.created | 2019-11-25 | - |
dc.date.created | 2019-11-25 | - |
dc.date.issued | 2019-10 | - |
dc.identifier.citation | European Journal of Cancer, Vol.120, pp.20-30 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.other | 86814 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177197 | - |
dc.description.abstract | Background: The phase III OlympiAD study (NCT02000622) showed a statistically significant progression-free survival benefit with olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA mutation and human epidermal growth factor receptor 2-negative metastatic breast cancer. From this study, we report the effect of olaparib on health-related quality of life (HRQoL). Methods: Patients were randomised 2:1 to olaparib monotherapy (300 mg twice daily) or single-agent TPC. The primary HRQoL end-point was mean change from baseline in the two-item global health status/QoL score determined from patient-completed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module (EORTC QLQ-C30) questionnaires and assessed using a mixed model for repeated measures. Symptoms and functioning domains, best overall response and time to deterioration of QoL were also evaluated. Results: Overall questionnaire compliance rates were 93.2% for olaparib and 76.3% for TPC. Between-treatment global health status/QoL comparison showed a significant improvement in the olaparib arm versus the TPC arm, with mean change of 3.9 (standard deviation 1.2) versus -3.6 (2.2), a difference of 7.5 points (95% confidence interval [CI]: 2.48, 12.44; P = 0.0035). A higher proportion of patients in the olaparib arm showed a best overall response of 'improvement' in global health status/QoL (33.7% vs 13.4%). Median time to global health status/QoL deterioration was not reached in olaparib patients and was 15.3 months for TPC patients (hazard ratio: 0.44 [95% CI: 0.25, 0.77]; P = 0.004). For EORTC QLQ-C30 symptoms and functioning subscales, only nausea/vomiting symptom score was worse in the olaparib arm than in the TPC arm (across all visits compared with baseline). Conclusion: HRQoL was consistently improved for patients treated with olaparib, compared with chemotherapy TPC. (C) 2019 The Authors. Published by Elsevier Ltd. | - |
dc.language | 영어 | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.title | Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1016/j.ejca.2019.06.023 | - |
dc.citation.journaltitle | European Journal of Cancer | - |
dc.identifier.wosid | 000487253300003 | - |
dc.identifier.scopusid | 2-s2.0-85070926015 | - |
dc.citation.endpage | 30 | - |
dc.citation.startpage | 20 | - |
dc.citation.volume | 120 | - |
dc.identifier.sci | 000487253300003 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EUROPEAN-ORGANIZATION | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordAuthor | Olaparib | - |
dc.subject.keywordAuthor | OlympiAD | - |
dc.subject.keywordAuthor | Health-related quality of life | - |
dc.subject.keywordAuthor | EORTC QLQ-C30 | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | BRCA | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.